AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06510764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziyinxiehuo Granules of traditional Chinese Medicine
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
Study NCT06510764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziyinxiehuo Granules of traditional Chinese Medicine
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
Study NCT05959291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of Anti-HER-2 Maintenance Treatment
Description: Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
Study NCT04987905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice).
Study NCT04954820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: 2 additional infusions of Lutathera®
Study NCT05099445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCB000928 200 mg will be administered on Day 1 of each treatment period.
Study NCT04831554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single chest tube drainage
Description: place single chest tube after surgery of PSP
Study NCT04991610 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: computed tomography
Description: CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
Study NCT06092450 — intervention group
Intervention type: OTHER
Intervention: develop and validate a deep learning radiomics model based on preoperative enhanced CT image
Description: develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
Study NCT06466707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of microbiome samples
Description: Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
Study NCT05452785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 (Minocycline) Fasting
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Study NCT05452785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 (Minocycline) Fed
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
Study NCT05452785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solodyn (Minocycline) Fasting
Description: In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
Study NCT04630834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
Study NCT04630834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
Study NCT04630834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
Study NCT04630834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
Study NCT06401031 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Press Needle
Description: Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
Study NCT06463028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Oral
Study NCT06463028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: Oral
Study NCT06463028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Infusion
Study NCT05562960 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasmapheresis
Description: Regular plasmapheresis to remove anti-NRIP autoantibody
Study NCT05922696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 50.000IU weekly in Group A , or 200.000IU monthly in Group B
Study NCT05679505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous vagus nerve stimulation
Description: Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
Study NCT06388213 — intervention group
Intervention type: DEVICE
Intervention: Gastric Ultrasonography
Description: Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
Study NCT06474169 — intervention group
Intervention type: OTHER
Intervention: 1 blood sample for each participant
Description: Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)
Study NCT04847921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: long-acting lipoglycopeptide antibacterial agent
Study NCT06372977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: kappa index
Description: CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
Study NCT06448663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin, fructooligosaccharides, inulin
Description: The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed.
Study NCT06448663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin
Description: The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed.
Study NCT05229133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR
Description: FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
Study NCT06018285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Approach to Reducing Risk of Suicide in Primary Care
Description: Intervention consists of implementation of clinical pathway for youth suicide risk
Study NCT06493799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAENNEC (Human Placenta Hydrolysate) IV
Description: Intravenous Injection
Study NCT05315063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
Study NCT06493799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAENNEC (Human Placenta Hydrolysate) SC
Description: Subcutaneous Injection
Study NCT05315063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (PIR)
Description: The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done
Study NCT06432777 — intervention group
Intervention type: OTHER
Intervention: Characteristics of patients and Campylobacter bacteraemia episodes
Description: Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
Study NCT04813510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment.
Study NCT04813510 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group
Study NCT05401071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 10mg/kg
Description: rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
Study NCT05401071 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Regimen
Description: During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, >71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, >71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, >71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, >71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, >50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally.
Study NCT05401071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 15mg/kg
Description: rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
Study NCT05401071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Regimen with Rifapentine 20mg/kg
Description: rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, >71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
Study NCT05420896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
Study NCT04402593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Heidelberg Model of Neuro-Music Therapy
Description: 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
Study NCT05233995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Damage Control Surgery
Description: Delayed anastomosis
Study NCT05233995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Damage Control Surgery
Description: Delayed anastomosis
Study NCT05564195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postoperative cognitive function
Description: Digital cognitive tests - Mindmore-P, will be used to assess neurocognitive capacity and includes tests of verbal episodic memory, executive functions, visuospatial function and attention. The cognitive tests are self-administered on a touch screen tablet (10.1 20-30 min Windows). The Mindmore-P is a web-application running on a full-screen Chrome browser. The test is administered by using a capacitive touchscreen with features that record detailed information such as timing, pauses, and lifting of finger from the touchscreen. Speech recognition is used in the screening of verbal memory and language.
Study NCT05618067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise training
Description: Participants will engage in weekly breathing exercises. They will be trained once a week for 4 weeks, and will use an app called Inner Balance and an device called Firstbeat Bodyguard 3 to track data about their hearts while practicing the exercises at home for 10 minutes a day, twice a day, once before bedtime.
Study NCT05660421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given by mouth
Study NCT05660421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Given by mouth or by vein
Study NCT05660421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Procedure
Description: Undergo endoscopic procedure
Study NCT05660421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Undergo skin biopsy
Study NCT05660421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool
Study NCT04303663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibular Plate
Description: ORIF with Plating
Study NCT04303663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibular Nail
Description: CRIF +/- ORIF with Fibular nail
Study NCT06331338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Cycle for Person-Centered Glycemic Management
Description: It is defined as a purposefully designed holistic care intervention that improve self-management .
Study NCT06331338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional diabetes self-management education
Description: Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
Study NCT04805411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study NCT04805411 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05362786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Description: Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
Study NCT05362786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)
Description: Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
Study NCT06132867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib oral solution
Study NCT06198257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spider cage
Description: 5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
Study NCT06198257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified suits therapy
Description: 5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse events collection
Description: Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse events collection
Description: Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire EQ-5D-5L
Description: Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire EQ-5D-5L
Description: Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical-economic evaluation
Description: Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS).
Study NCT06294028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical-economic evaluation
Description: Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS).
Study NCT06205030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-diabetic herbal drug
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.